Details for Patent: 9,345,771
✉ Email this page to a colleague
Which drugs does patent 9,345,771 protect, and when does it expire?
Patent 9,345,771 protects SYNDROS and is included in one NDA.
Summary for Patent: 9,345,771
| Title: | Oral cannabinoid formulations |
| Abstract: | Oral cannabinoid formulations, including an aqueous-based oral dronabinol solution, that are stable at room or refrigerated temperatures and may possess improved in vivo absorption profiles with faster onset and lower inter-subject variability. |
| Inventor(s): | Venkat R. Goskonda, Ashok Chavan, Amit Kokate, Howard Gill |
| Assignee: | Wellhouse Pharma LLC |
| Application Number: | US13/644,283 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,345,771 |
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Compound; Dosage form; |
More… ↓ |
Drugs Protected by US Patent 9,345,771
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Benuvia Operations | SYNDROS | dronabinol | SOLUTION;ORAL | 205525-001 | Mar 23, 2017 | DISCN | Yes | No | ⤷ Try for Free | ⤷ Try for Free | Y | Y | ⤷ Try for Free | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
